Authorized purpose: The Biograph Vision and Biograph mCT family are combined PET/CT systems for acquiring, reconstructing, fusing, displaying, evaluating, and archiving PET and CT studies for trained nuclear-medicine and radiology professionals across labeled oncology, cardiology, neurology, and radiotherapy-planning workflows.
Clinical role
PET/CT acquisition, reconstruction, attenuation correction, fusion, visualization, and quantitative review.
Images and patients
PET/SPECT/Nuclear Medicine · Multi-region
Key limitation
Keep in mind: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific; diagnostic and treatment decisions remain with qualified clinicians.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: The Biograph Vision and Biograph mCT family are combined PET/CT systems for acquiring, reconstructing, fusing, displaying, evaluating, and archiving PET and CT studies for trained nuclear-medicine and radiology professionals across labeled oncology, cardiology, neurology, and radiotherapy-planning workflows.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Multi-region Input: Positron-emission data, CT transmission data, patient and protocol information, and supported radiopharmaceutical studies.
Who uses it?Intended users: Qualified nuclear medicine physicians, radiologists, technologists, and other trained PET/CT professionals.
What does the software produce?Output: Attenuation-corrected PET, CT, fused PET/CT, quantitative, and planning images for professional interpretation.
What is its most important limitation?Key limitation: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific; diagnostic and treatment decisions remain with qualified clinicians.
Clinical takeaway. Clinical role: The Biograph Vision and Biograph mCT family are combined PET/CT systems for acquiring, reconstructing, fusing, displaying, evaluating, and archiving PET and CT studies for trained nuclear-medicine and radiology professionals across labeled oncology, cardiology, neurology, and radiotherapy-planning workflows.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports PET testing per NEMA NU2-2018 on Biograph Vision 6-ring and 8-ring and Biograph mCT 3-ring and 4-ring configurations; CT subsystem testing was in the original premarket notification. All features met predetermined verification and validation acceptance criteria. FlowMotion AI successful bed-range identification ranged from 87.1% to 100% by configuration; OncoFreeze AI SUV and volume changes were compared with Anzai based OncoFreeze; whole body scatter correction was evaluated in a phantom simulation study. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
The Biograph Vision and Biograph mCT family are combined PET/CT systems for acquiring, reconstructing, fusing, displaying, evaluating, and archiving PET and CT studies for trained nuclear-medicine and radiology professionals across labeled oncology, cardiology, neurology, and radiotherapy-planning workflows.
The exact FDA document reports PET testing per NEMA NU2-2018 on Biograph Vision 6-ring and 8-ring and Biograph mCT 3-ring and 4-ring configurations; CT subsystem testing was in the original premarket notification. All features met predetermined verification and validation acceptance criteria. FlowMotion AI successful bed-range identification ranged from 87.1% to 100% by configuration; OncoFreeze AI SUV and volume changes were compared with Anzai based OncoFreeze; whole body scatter correction was evaluated in a phantom simulation study. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Performance testing for the CT subsystem was included in the original premarket notification for the CT subsystems" … "PET Testing in accordance with NEMA NU2-2018 was conducted on two different configurations of the Biograph Vision systems, a 6-ring version and an 8-ring version and on two configurations of the Biograph mCT, a 3-ring version and a 4-ring version.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports PET testing per NEMA NU2-2018 on Biograph Vision 6-ring and 8-ring and Biograph mCT 3-ring and 4-ring configurations; CT subsystem testing was in the original premarket notification. All features met predetermined verification and validation acceptance criteria. FlowMotion AI successful bed-range identification ranged from 87.1% to 100% by configuration; OncoFreeze AI SUV and volume changes were compared with Anzai based OncoFreeze; whole body scatter correction was evaluated in a phantom simulation study. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Performance testing for the CT subsystem was included in the original premarket notification for the CT subsystems" … "PET Testing in accordance with NEMA NU2-2018 was conducted on two different configurations of the Biograph Vision systems, a 6-ring version and an 8-ring version and on two configurations of the Biograph mCT, a 3-ring version and a 4-ring version.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-03
Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K193248 FDA performance package for Biograph Vision, Biograph mCT Family of PET/CTs
DesignManufacturer PET/CT hardware, acquisition, reconstruction, software, DICOM, image-quality, dose, safety, EMC, and usability verification and validation submitted in K193248
PopulationPET/CT examinations across the labeled radiopharmaceutical, scan-range, anatomy, oncology, cardiology, neurology, and radiotherapy-planning workflows
Scopeexact submission
Tested versionBiograph Vision and Biograph mCT Family of PET/CTs (K193248)
IndependenceSponsor or vendor study
K193248
Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
2 exact-submission FDA recall records in the 2026-09-02 openFDA snapshot identify K193248. Affected model, version, unit, correction, and current manufacturer instructions still require local confirmation. FDA recall Z-1135-2023 is Open, Classified for SIEMENS Biograph mCT: a) Flow 64-4R Seismic, b) S(40)-3R Seismic, c) S(64)-3R Seismic, d) S(40)-4R Seismic, e) S(64)-4R Seismic, f) S(20)-3R Mobile. FDA reason: This is a potential problem with the locking mechanism that is used to secure the PET gantry in either its scanning or service position. FDA action: SIEMENS Healthineers distributed a Consumer Safety Advisory Notice to its consignees on 01/16/2023 by mail and email. The notice explained the issue and recommended that the following preventive actions be taken until a local Siemens Healthineers service representative has applied the correction: "Mitigation for Biograph Mobile Installations Ensure that the PET/CT Gantry offset protocol is performed every time the coach has moved. If the PET/CT gantry offset fails due to the results being out of tolerance, please cease clinical operations on the system and contact your local Siemens Healthineers service representative for further evaluation and guidance on how to proceed. Information on how to acquire the PET/CT Gantry offset protocol is documented in your user documentation. Mitigation for Biograph Seismic Installations In the event of a seismic event, contact your local Siemens Healthineers service representative for further evaluation and guidance on how to proceed. Siemens Healthineers will begin dispatching customer service engineers by the end of February 2023 to inspect and make corrections to the locking mechanism to prevent the occurrence of this issue. The resolution for this issue will be delivered by the following Update Instruction: MI516/22/S. Please ensure that this notice is placed in the Biograph Operator Manual and disseminated to all operators of the scanner." "If you have any questions regarding this advisory notice, please contact your local Siemens Healthineers representative at the contact numbers provided below. America: 1-800-888-7436 Europe, Middle East, and Africa: +49 9131 940 4000 Asia and Australia: +86 (21) 3811 2121" FDA recall Z-1136-2023 is Open, Classified for SIEMENS Biograph Vision: a) 450, b) 600, c) 600 Edge. FDA reason: This is a potential problem with the locking mechanism that is used to secure the PET gantry in either its scanning or service position. FDA action: SIEMENS Healthineers distributed a Consumer Safety Advisory Notice to its consignees on 01/16/2023 by mail and email. The notice explained the issue and recommended that the following preventive actions be taken until a local Siemens Healthineers service representative has applied the correction: "Mitigation for Biograph Mobile Installations Ensure that the PET/CT Gantry offset protocol is performed every time the coach has moved. If the PET/CT gantry offset fails due to the results being out of tolerance, please cease clinical operations on the system and contact your local Siemens Healthineers service representative for further evaluation and guidance on how to proceed. Information on how to acquire the PET/CT Gantry offset protocol is documented in your user documentation. Mitigation for Biograph Seismic Installations In the event of a seismic event, contact your local Siemens Healthineers service representative for further evaluation and guidance on how to proceed. Siemens Healthineers will begin dispatching customer service engineers by the end of February 2023 to inspect and make corrections to the locking mechanism to prevent the occurrence of this issue. The resolution for this issue will be delivered by the following Update Instruction: MI516/22/S. Please ensure that this notice is placed in the Biograph Operator Manual and disseminated to all operators of the scanner." "If you have any questions regarding this advisory notice, please contact your local Siemens Healthineers representative at the contact numbers provided below. America: 1-800-888-7436 Europe, Middle East, and Africa: +49 9131 940 4000 Asia and Australia: +86 (21) 3811 2121"
FDA source
Exact FDA submission
Checked 2026-09-04
Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.
Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Positron-emission data, CT transmission data, patient and protocol information, and supported radiopharmaceutical studies.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: PET/CT console and DICOM workflow to PACS, oncology, radiotherapy, or reporting systems; validate radiopharmaceutical labels, patient matching, attenuation maps, series labels, SUV or quantitative values, and routing.
Scope: Product family. Current vendor materials are product-family evidence for K193248; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: Installed PET/CT scanner, console, reconstruction options, and supported clinical or radiotherapy interfaces.
Scope: Product family. Current vendor materials are product-family evidence for K193248; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Attenuation-corrected PET, CT, fused PET/CT, quantitative, and planning images for professional interpretation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Installed PET/CT scanner, console, reconstruction options, and supported clinical or radiotherapy interfaces.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K193248; confirm the exact cleared version, enabled options, deployment, and local compatibility.
PET/CT console and DICOM workflow to PACS, oncology, radiotherapy, or reporting systems; validate radiopharmaceutical labels, patient matching, attenuation maps, series labels, SUV or quantitative values, and routing.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K193248; confirm the exact cleared version, enabled options, deployment, and local compatibility.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Only qualified nuclear medicine physicians, radiologists, technologists, and other trained pet/ct professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific; diagnostic and treatment decisions remain with qualified clinicians.
Product family
Checked 2026-09-03
Current vendor materials are product-family evidence for K193248; confirm the exact cleared version, enabled options, deployment, and local compatibility.
PET/CT console and DICOM workflow to PACS, oncology, radiotherapy, or reporting systems; validate radiopharmaceutical labels, patient matching, attenuation maps, series labels, SUV or quantitative values, and routing.
product family · checked 2026-09-03
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific; diagnostic and treatment decisions remain with qualified clinicians.
exact submission · checked 2026-09-03
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03
No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Radiopharmaceutical, scan range, patient-size, acquisition, reconstruction, attenuation-correction, dose, and quantitative limits are configuration-specific; diagnostic and treatment decisions remain with qualified clinicians.
product family · checked 2026-09-03
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 2 FDA recall candidates were manually reviewed: 2 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 2 postmarket candidate records; 2 have been reviewed (2 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Authorized purpose: Vereos PET/CT detects, localizes, diagnoses, stages, restages, and follows treatment response in oncology, cardiology, and neurology and can provide diagnostic CT and radiotherapy-planning support; optional PET Adaptive Reconstruction is an AI-powered image-reconstruction function.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.